請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16240
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 游若萩(Roch-Chui Yu) | |
dc.contributor.author | Chen-Hsin Hsu | en |
dc.contributor.author | 徐陳欣 | zh_TW |
dc.date.accessioned | 2021-06-07T18:06:20Z | - |
dc.date.copyright | 2012-07-27 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-07-24 | |
dc.identifier.citation | 王舒徽。2000。原生菌之機能性介紹。食品工業。32:741-751。
王瑋琦。2010。乳酸菌之抗發炎與改善潰瘍性腸炎功效評估。國立陽明大學生物暨分子生物所碩士學位論文。台北。台灣。 行政院衛生署。2003。健康食品之胃腸功能改善評估方法。行政院衛生署公告衛署食字第0920401629號。行政院衛生署。台北。台灣。 李逸華。2011。數株乳酸桿菌胞外多醣之抗發炎作用及抑制結腸癌細胞增生之研究。國立台灣大學食品科技所碩士學位論文。台北。台灣。 陳穗葶。2005。數株乳酸菌胞外多醣對雙叉桿菌生長之助生性研究。國立臺灣大學食品科技研究所碩士學位論文。台北。台灣。 劉曲婷。2010。餵食 Lactobacillus casei 01 及其胞外多醣對 1,2-二甲基聯胺誘導 F344 大鼠結腸癌前病變之影響。國立臺灣大學食品科技研究所博士學位論文。台北。台灣。 廖啟成。1998。乳酸菌之分類及應用。食品工業。30:1-10。 Aattouri, N.; Lemonnier, D. Production of interferon induced by Streptococcus thermophilus: role of CD4+ and CD8+ lymphocytes. J. Nutr. Biochem.1996,8,24-31. Alex, P.; Zachos, N.C.; Nguyen, T.; Gonzales, B. S.; Chen, T. E.; Conkin, L.; Centola, M.; Li, Xuhang. Distinct cytokine patterns identified from mulitiplex profiles of murine DSS and TNBS-induced colitis.Inflam. Bowel Dis.2009, 15, 341-352. Arunachalam, K. D. Role of bifidobacteria in nutrition, medicine and technology. Nutr. Res. 1999, 19, 1559-1597. Berg, D. J.; Davidson, N.; Kuhn, R.; Muller, W.; Menon, S.; Holland, G.; Thompson- Snipes, L.; Leach, M. W.; Rennick, D. Enterocolitis and colon cancer in interleukin -10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.J.Clin.Invest.1996,98,1010-1020. Borruel, N.; Carol, M.; Casellas, F.; Antolin, M.; de Lara,F.; Espin, E.; Naval, J.; Guarner, F.; Malagelada, J. R. Increased mucosal tumour necrosis factor a production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria.Gut. 2002, 51,659-664. Brashears, M. M.; Gillil, S. E.; Buck, L. M. Bile salt deconjugation and cholesterol removeal from media by Lactobacillus casei. J. Dairy Sci. 1998,81,2103-2110. Buelens, C.; Verhasselt, V.; Groote, D.D.; Thielemans, K.; Goldman, M.; Willems, F. Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10. Eur. J. Immunol.1997, 27, 1848-1852. Cerning, J. Exocellular polysaccharides produced by lactic acid bacteria. FEMS Microbiol. Lett.1990, 87, 739-758. Cerning, J. Production of exopolysaccharides by lactic acid bacteria and dairy propioni- bacteria. Le Lait.1995, 75, 463-472. Cross, M. L.; Stevenson, L. M.; Gill, H. S. Anti-allergy properties of fermented foods: An important immunoregulatory mechanism of lactic acid bacteria? Int. Immunopharmacol.2002, 1, 891-901. Daeschel, M. A. Antimicrobial substances from lactic acid bacteria for use as food preservatives. Food Technol. 1989, 43, 164-166. De Vries, W.; Stouthamer, A. H. Fermentation of glucose, lactose, galactose, mannitol, and xylose by Bifidobacteria. J. Bacteriol. 1968, 96, 472-478. De Vuyst, L.; Degeest B.Heteropolysaccharides from lactic acid bacteria. FEMS Microbiol Rev.1999, 23, 153-177. De Vuyst, L.; Vaningelgem, F.; De Vin,F.; Degeest, B.; Recent developments in the biosynthesis and applications of heteropolysaccharides from lactic acid bacteria. Int. Dairy J. 2001, 11, 687-708. Doleyres Y, Schaub L, Lacroix C. 2005. Comparison of the functionality of exopolysaccharides produced in situ or added as bioingredients on yogurt properties. J Dairy Sci. 2005, 88, 4146-4156. Dubois, M., Gilles, K. A., Hamilton, J. K., Rebers, P. A., Smith, F. Colorimetric method for determination of sugars and related substances. Anal. Chem. 1956, 28, 350-356. Ekbom, A.; Helmick, C.; Zack, M.; Adami, H. O. Ulcerative colitis and colorectal cancer. 76 A population-based study. N. Engl. J. Med. 1990, 323, 1228-1233. FAO/ WHO. Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Report of a Joint FAO/ WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Córdoba, Argentina, October 1-4, 2001. Forsen, R.; Heiska, E.; Herva, E.; Arvilommi, H.; Immunobiologic effect of Steptococcaus cremoris from cultured milk “viili”,application of human lymphocyte culture techniques. Int. J. Food Microbiol. 1987, 5, 41-47. Fukushima, M.; Nakano, M. Effects of a mixture of organisms, Lactobacillus acidophilus or Streptococcus faecalis on cholesterol metabolism in rats fed on a fat- and cholesterol-enriched diet. Br. J. Nutr. 1996,76, 587-867. Fukushima, Y.; Kawata, Y.; Hara, H.; Terada, A.; Mitsuoka, T. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int. J. Food Microbiol. 1998, 42, 39-44. Fuller, A. Probiotics in man and animals. J. Appl. Microbiol.1989, 66, 365-378 Fuss, I. J.; Neurath, M.; Boirivant, M. Disparate CD4+ lamina propria(LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma. Whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 1996, 157,1261-1270. Gaya, D.R.; Russell, R. K.; Nimmo, E.R.; Satsangi, J. New genes in inflammatory bowel disease: Lessons for complex disease? Lancet. 2006, 279, 821-823. Gilliland, S. E.; Fuller, R. Aspects of in vitro and in vivo research approaches direxted toward identifying probiotics and prebiotics for human use. J. Nutr. 2000, 130, 391-395 Gilliland, S. E.; Kim, H. S. Effect of viable starter culture bacteria in yogurt on lactose utilization in humans. J. Dairy Sci.1984, 67, 1-6 Goldin, B. T.; Gorbach, S. L. The effect of milk and Lactobacillus feeding on human intestinal bacterial enzyme activity. Am. J. Clin. Nutr. 1984, 39, 756-761. Gorbach, S. L. The intestinal microflora and its colon cancer connection. Infection. 1982, 10, 379-384. Griess, P. Bemerkungen zu der Abhandlung der HH. Weselky and Benedikt Ueber einige Azoverbindungen. Berichte der Deutschen chemischen. 1879, 12, 426-428. Grobben, G. J.; Boels, I. C.; Sikkema, J.; Smith, M. R.; Bont, J. A. M. Influenceions on growth and production of exopolysaccharides by Lactobacillus delbrueckil subsp. Bulgaricus NCFB 2772. J. Dairy. Res. 2000, 67, 131-135. Hugot, J. P.; Laurent-Puing, P.; Gower-Rousseau, C. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature. 1996, 379, 821-823. Hull RR, Conway, P. L.; Evans, A. J. Probiotics food-a new opportunity. Food Aust. 1992, 44, 112-113. Ihle, J. N.; Cytokine receptor signaling. Nat. 1995, 377, 591-594. Isolauri, E.; Arvola, T.; Sutas, Y.; Moilanen, E.; Salminen, S. Probiotics in the management of atopic excema. 2000, 30,1604-1610. Jackson et al. Sample TNBS-induced IBD protocol. JAX In Vivo Services. 2008. Karpuzoglu, E.; Ahmed, S. A. Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: Implications for immunity,autoimmune diseases, and apoptosis. Nitric Oxide. 2006, 15, 177-186. Kitazawa, H.; Itoh, T.; Tomioka, Y.; Mizugaki, M.; Yamaguchi, T. Induction IFN-γand IL- 1α production in macrophages stimulated with phosphopolysaccharide produced by Lactobacillus lactis spp. cremoris. Int. J. Food Microbiol. 1996, 31, 99-106. Kitazawa, H.; Toba, T.; Itoh, T.; Kumano, N.; Adachi, S.; Yamaguchi, T. Antitumoral activity of slime-forming encapsulated Lactococcus lactis subsp. cremoris isolated from Scandinavian ropy sour milk, “viili”. Anim. Sci. Technol. 1991, 62, 277-283. Kitazawa, H.; Harata, T.; Uemura, J.; Daito, T.; Kaneko, T.; Itoh, T. Phosphate group requirement for mitogenic activation of lymphocytes by an extracelluar phosphopolysaccharide from Lactobacillus delbrueckii subsp. bulgaricus. Int. J. Food Microbiol. 1998, 40, 169-175. Kitazawa, H.; Yamaguchi, T.; Itoh, T. B-cell mitogenic activity of slim products produced from slim-forming encapsulated Lactobacillus lactis subsp. cremoris. J. Dairy Sci. 1992, 75, 2946-2951. Klaver, F. A. M.; Vam der meer, R. The assumed assimilation of cholesterol by lactobacilli and Bifidobacterium bifidum is due to their bile salt-deconjugating activity. Appl. Environ. Microbiol. 1993, 59, 1120-1124. Knowles, R.G.; Moncada, S. Nitric oxide synthases in mammals. Biochem. J. 1996, 24, 875-878. Krawisz, J. B.; Sharon, P.; Stenson, W. E. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity.Gastronterology. 1984, 87, 1344-1350. Krimsky, K.; Yedgar,S.; Aptekar, L.; Schwob, O.; Goshen, G.; Gruzman, A.; Sasson, S.; Ligumsky, M. Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor. Am. J. Phys. 2003, 285, 586-592. Kurata, J. H.; Kantor-Fish, S.; Frank, H.; Godby, P.; Vadheim, C. M. Crohn’s disease among ethnic group in a large health maintenance organization. Gastroenterology. 1992, 102, 1940-1948. Laws, A.; Gu, Y.; Marshall, V.; Biosynthesis, characterization, and design of bacterial exopolysaccharides from lactic acid bacteria. Biotechnol. Adv. 2001, 19, 597- 625. Laws, A. P.; Marshall, V. M. The relevance of exopolysaccharides to the rheological properties in milk fermented with ropy stains of lactic acid bacteria. Int. Dairy. 2011, 11, 709-721. Lee, Y. K.; Salminen, S. The coming of age of probiotics. Trenda in Food Sci. Technol. 1995, 6, 241-245. Liu, L.; Wang, Z. P.; Xu, C. T.; Pan, B. R.; Mei, Q. B.; Long, Y.; Liu, J. Y.; Zhou, S. Y. Effects of Rheum tanguticum polysaccharide on TNBS- induced colitis and CD4+T cell in rats.World J. Gastroenterology.2003, 9, 2284-2288. Lomer, M. C. E.; Parkes, G. C.; Sanderson, J. D. Review article: lactose intolerance in clinical practice – myths and realities. Aliment. Pharm. Therap. 2008, 27, 93-103. Looijesteijn P. J.; Trapet L, de Vries E, Abee T, Hugenholtz J. Physiological function of exopolysaccharides produced by Lactococcus lactis. Int. J. Food Microbiol. 2001, 64, 71-80. Looijesteijn, P. J., van Casteren, W. H. M.; Tuinier, R.; Doeswijk-Voragen, C. H. L.; Hugenholtz, J. Influence of different substrate limitations on the yield, composition and molecular mass of exopolysaccharides produced by Lactococcus lactis subsp. Cremoris in continuous cultures. J. App. Microbiol. 2000, 89, 116-122. Low, D.; J. A.; Ahlgren, D.; Horne, D.J.; McMahon, C. J.; Oberg; Broadbent, J. R. Role of Streptococcus thermophilus MR.1C capsular exopolysaccharide in cheese moisture retention. Appl. Environ. Microbiol. 1998, 64, 2147-4151. Macpherson, A. J.; Uhr, T. Compartmentalization of the mucosal immune responses to commensal intestinal bacteria. Ann. N.Y. Acad. Sci. 2004. 1029, 36-43. Majamaa, H.; Isolauri, E. Probiotics: A novel approach in the management of food allergy. J. Allergy Clin. Immunol. 1997, 99, 179-185. Mevissen-Verhage EA, Marcelis JH, de Vos MN, Harmsen-van Amerongen WC, Verhoef J..Bifidobacterium, Bacteroides, and Clostridium spp. In fecal samples from breast-fed and bottle-fed infants with and without iron supplement. J. Clin .Microbiol. 1987, 25, 285-2889. Molder, H. W.; Mckellar, R. C.; Yaguchi, M. Bifidobacteria and bifidogenic factors. Can. Inst Food Sci Technol.1990, 23, 29-41. Monsan, P.S.; Bozonnet, C.; Albenne, G.; Joucla, R. M.; Willemot, M.; Monsan, R. S. Homopolysaccharides from lactic acid bacteria. Int. Dairy J. 2001, 11, 675-686. O’Shea. J. J.; Murray, P. J.; Cytokine signaling modules in inflammatory responses. Immunity. 2008, 28, 477-487. Parvez, S.; Malik, K. A.; Ah Kang, S.; Kim, H. Y. Probiotics and their fermented food products are beneficial for health. J. Appl. Microbiol. 2006, 100, 1171-1185. Peran, L.; Camuesco, D.; Comalada, M.; Nieto, A.; Concha, A.; Olivares, M.; Xaus, J.; Zarzuelo, A.; Galvez, J. Preventative effects of a probiotic, Lactobacillus salivarius ssp.salivarius, in the TNBS model of rat colitis.World J. Gastroenterol. 2005, 33, 5185-5192. Phillippe, D.; Heupel, E.; Blum-Sperisen, S.; Riedel, C. U. Treatment with Bifidobacterium bifidum 17 partially protects mice from Th1-driven inflammation in a chemically induced model of colitis. Int. J. Food Microbiol. 2011, 149, 45-49. Ransohoff, D. F. Colon cancer in ulcerative colitis. Gastroenterology. 1988, 94, 1089-1091. Rogler, G.; Andus, T. Cytokines in Inflammatory Bowel Disease. World. J. Surg. 1998, 22, 382-389. Ruas-Madiedo, P.; de los Reyes-Gavilán, C. G. Invited review: Methods for the screening, isolation, and characterization of exopolysaccharides produced by lactic acid bacteria. J. Dairy Sci. 2005, 88, 843-856. Ruas-Madiedo, P.; Hugenholtz, J.; Zoon, P.; An overview of the functionality of exopolysaccharides produced by lactic acid bacteria. Int. Dairy J. 2002, 12, 163-171. Russel, R. K.; Satsangi, J.; IBD: A family affair. Best Pract. Res. Clin. Gastroenterol.2004, 18, 525-539. Rutgeerts, P.; Van Assche, G.; Vermeire, S. Optimizing Anti-TNF Treatment in Inflammatory Bowel Disease. Gastroenterology. 2004, 126, 1593-1610. Saarela, M.; Lahteenmaki, L.; Crittenden, R.; Salminen, S.; Mattila-Sandholm,T. Gut bacteria and health foods-the European perspective. Int. J. Food Microbiol. 2002, 78, 99-117. Salminen, S,; Isolauri, E,; Salminen, E. Probiotics and stabilizartion of the gut mucosal barrier. Asia Pacific J. Clin. Nutr. 1996, 5, 53-56. Scheiffele, F.; Fuss, I.V. Induction of TNBS colitis in mice. Curr. Protocol In Immunol. 2001, 15, 15.19.1-15.19.14. Scheinbach, S. Probiotics: Functionality and commercial status. Biotechnol. Adv. 1998, 16, 581-608 Schreiber, S.; Heinig, T.; Thiele, H. G.; Raedler, A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology. 1995, 108, 1434-1444. Şengűl, N.; Aslīm, B.; Uçar, G.; Yűcel, N.; Işik, S.; Bozkurt, H.; Sakaoğullari, Z.; Atalay, F. Effects of exopolysaccharide-producing probiotic strains on experimental colitis in rat. Dis. Colon Rectum. 2005, 49, 250-258. Sengul, N.; Isik, S.; Aslm, B.; Ucar, G.; Demirbag, A. E. The Effect of exopolysaccharide producing probiotic strains on gut oxidative damage in experimental colitis inflammation in a chemically induced model of colitis . Food microbiol. 2010, 56, 707-714. Shanahan F. Inflammatory bowel disease: immunodiagnostics, Immunotherapeutics and ecotherapeutics. Gastroenterology. 2001, 120, 622-635. Sharon, P.; Stenson, W. F.; Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.Gastroenterology. 1984, 86, 453-460. Sokol, H.; Antand-Pigneur, B.; Watterlot, L.; Lakhdari, O.; Blottiere, H. M.; Grangette, C.; Trugnan, G.; Dore, J. M.; Thomas, G.; Marteau, P. R.; Seksik, P.; Langella, P. Faecalibacterium prausnitzii is an anti- inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Gastroenterology. 2008, 134, A359-A359. Stallmach, A.; Giese, T.; S; Schmidt, C.; Ludwig, B.; Mueller-Molaian, I.; Meuer, S. C. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn’s diease. Int. J. Colorectal Dis. 2004, 19, 308-315. Strober, W.; Fuss, I. J.; Blumberg, R. S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 2002, 20, 495-549. Stucchi, A. F.; Shofer, S.; Leeman, S.; Materne, O.; Beer, E.; McClung, J. Shebani, K.; Moore, F.; O’Brien, M.; Becker, J. M. NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am. J. Physiol. 2000, 279, 1298-1306 Swirski et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009, 325, 612-616. Tamir, S.; Tannenbaum, S. R. The role of nitric oxide (NO〃) in the carcinogenic process. Biochim. Biophys. Acta.1996, 1288, F31-F36. Torino, M. I.; Sesma, F.; Valdez, F. Semi-defined media for the exopolysaccharides (EPS) production by Lactobacillus helveticus ATCC 15807 and evaluation of the components interfering with the EPS quantification. Milchwissenschaft. 2000, 55, 314-316. Van Geel-Schuttern, G. H., Flesch, F., ten Brink, B., Smith, M. R., Dijkhuizen, L. Screening and characterization of Lactobacillus strains producing large amounts of exopolysaccharides. Appl. Microbiol. Biotechnol. 1998, 50, 697-703. Welman, A. D.; Maddox, L. D. Exopolysaccharides from lactic acid bacteria: perspectives and challenges. Trends Biotechnol. 2003, 21, 269-274. Wheeler, J. G.; Shema, M. A.; Stine, K. C.; Pittler, A. J.; Burks, A. W.; Helm, R. M. Impact of dietary yogurt on immune fuction. Am. J. Med. Sci.1997, 313, 120-123. Wirtz, S.; Neufert, C.; Weigmann, B. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007, 2, 541-546. Wu, M. H.; Pan, T. M.; Wu, Y. J.; Chang, S. J.; Chang, M. S.; Hu, C. Y. Exopolysaccharide activities from probiotics bifidobacterium: Immunomodulatory effect (on J774A.1 macrophages) and antimicrobial properties. Int. J. Food Microbiol. 2010,144, 104-110. Yosuke, K.; Takeshi, T.; Katsushige, Y.; Tsukasa, I.; Masaru, Y. Takeshi, A.; Masashi, M. Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. Int. Immunol. 2009, 9, 1444-1451. Zubillaga, M.; Weill, R.; Postarie, E.; Goldman, C.; Caro, R.; Boccio, J. Effect of probiotics and functional foods and their use in different diseases. Nutr. Res. 2001, 21, 569-579. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16240 | - |
dc.description.abstract | 近年來,許多學者探討乳酸菌產生之胞外多醣(exopolysaccharide, EPS),對於健康有益。發炎性腸道疾病 (inflammatory bowel disease, IBD) ,可分為潰瘍性結腸 (ulcerative, UC) 和克隆氏症 (Crohn’s diease, CD),為一種慢性腸道疾病,但其致病機制尚未明了。本研究使用 Lactobacillus plantarum BCRC 11697產生之胞外多醣來探討其對三硝基苯磺酸 (trinitrobenzene sulfonic acid, TNBS ) 誘導成類似克隆氏症 (Crohn’s disease) 的動物模式中降低發炎之功效。結果顯示,餵食 EPS 或 L. plantarum BCRC 11697 菌株,再經過 TNBS 誘導成結腸炎,可明顯降低經 TNBS 誘導大鼠結腸炎後腸道出血現象和水樣便的發生,結腸短縮現象和脾臟腫脹現象也有所改善,而發炎指標骨髓過氧化酵素 (myeloperoxidase, MPO)、TNF-α 和 iNOS 表現量在經 TNBS 誘導後大量產生,代表有發炎的情況,而有餵食 EPS 或L. plantarum BCRC 11697 菌株,再經過 TNBS 誘導的組別,產量和表現量下降了,顯示發炎現象下降。而抗發炎細胞激素IL-10 可降低發炎的情況,檢測結果顯示,餵食 L. plantarum BCRC 11697 菌株再經 TNBS 誘導的組別其產生量較高。腸道氧化壓力有關的酵素 glutathione (GSH),經 TNBS 誘導大鼠結腸炎後,其還原態的 GSH 氧化成 GSSH,代表腸道氧化壓力提高,而餵食 EPS 或 L. plantarum BCRC 11697 菌株,再經誘導的組別,其還原態 GSH 的量提高。由以上結果的得知 L. plantarum BCRC 11697 益生菌和其萃取出的胞外多醣,對於大鼠結腸有保護作用,可降低TNBS對於結腸的傷害,進而降低發炎的情形和腸道氧化壓力,故對於發炎性腸道疾病中的克隆氏症有改善現象,其中又以餵食 L. plantarum BCRC 11697 益生菌的效果較佳。 | zh_TW |
dc.description.abstract | Recently, many studies had shown that exopolysaccharide (EPS) produced by LAB has health benefits. Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are characterized by chronic inflammation. The etiology and pathogenesis of IBD remains unknown. The aim of the present work is to investigate the anti-inflammatory activity of EPS produced by Lactobacillus plantarum BCRC 11697, on trinitrobenzene sulfonic acid (TNBS) induce rat colitis, which resembles human Cron’s disease (CD). Results showed that the TNBS-induced colitis rats had rectal bleeding, severe diarrhea with reduced colon length and spleen weight. The EPS treated rats and L. plantarum BCRC 11697-treated rats significantly reduced rectal bleeding, severe diarrhea and colon length. In addition, myeloperoxidase (MPO), TNF-α and iNOS expression in the TNBS-induced colitis rats was substantially increased, and the EPS treated rats and L. plantarum BCRC 11697 treated rats significantly reduced myeloperoxidase (MPO), TNF-α concentration and iNOS expression. Cytokine IL-10 could reduce inflammatory parameters, and L. plantarum BCRC 11697 treated rats was significantly increased. Finally, EPS treated rats and L. plantarum BCRC 11697 treated rats showed a significantly increasing in colonic GSH content, which is depleted in colonic rats as a consequence of the colonic oxidative stress induced by TNBS. These results showed that the administrated of EPS or L. plantarum BCRC 11697 could protect colonic tissue in the TNBS rats with reduced colonic inflammatory and oxidative stress. It could ameliorate Crohn’s disease (CD) of IBD, and administration of L. plantarum BCRC 11697 gets better effects as compared to EPS treatment. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T18:06:20Z (GMT). No. of bitstreams: 1 ntu-101-R99641031-1.pdf: 3095867 bytes, checksum: d003e28c589c667d3d44732610ba7d34 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 謝誌..................................................... i
中文摘要................................................. ii 英文摘要.................................................iii 目錄..................................................... v 圖目錄.................................................viii 表目錄................................................... x 前言..................................................... 1 壹、文獻整理............................................. 2 一、益生菌............................................ 2 (一)乳酸菌........................................ 2 (二)乳酸菌之分類.................................. 3 (三)乳酸菌之特性.................................. 4 (四)乳酸菌對健康的益處............................ 5 二、胞外多醣.......................................... 10 (一)乳酸菌胞外多醣................................ 10 (二)乳酸菌胞外多醣之分類、組成及結構.............. 12 (三)乳酸菌胞外多醣生合成.......................... 15 (四)乳酸菌胞外多醣的應用.......................... 17 三、發炎性腸道疾病.................................... 20 (一)造成發炎性腸道疾病可能原因.................... 20 (二)發炎性腸道疾病指標............................ 21 (三)改善發炎性腸道疾病方法........................ 22 四、發炎性腸道疾病之動物模式.......................... 27 (一)化學誘導發炎性腸道疾病........................ 27 (二)三硝基苯磺酸誘導結腸炎之特徵.................. 27 叁、材料與方法........................................... 31 一、實驗架構........................................... 31 二、實驗材料........................................... 34 (一)試驗菌株....................................... 34 (二)實驗動物....................................... 34 (三)微生物培養基................................... 34 (四)化學藥品....................................... 34 (五)儀器設備........................................35 (六)西方點墨法之抗體..................................... 37 (七)酵素連結免疫吸附分析之抗體套組................. 37 三、實驗方法........................................... 39 (一)胞外多醣的製備................................. 39 (二)胞外多醣含量測定................................39 (三)實驗動物....................................... 40 1.試驗設計...................................... 40 2.大鼠體重測量.................................. 41 3.大鼠腸道菌相分析.............................. 41 4.大鼠糞便潛血評分.............................. 42 5.結腸長度與重量測量............................ 43 6.結腸組織切片觀察.............................. 43 7.結腸細胞激素分析..............................44 8.結腸骨髓過氧化酵素濃度測定....................45 9.結腸Glutathione測定...........................45 10.結腸組織蛋白萃取............................. 46 11.結腸iNOS 測定................................ 46 (四)統計分析....................................... 47 肆、結果與討論........................................... 48 一、胞外多醣產量......................................... 48 二、大鼠的體重變化....................................... 48 三、糞便潛血評分......................................... 50 四、大鼠臟器重量變化..................................... 53 五、結腸長度測量......................................... 54 六、腸道微生物菌相....................................... 59 七、結腸組織切片觀察..................................... 59 八、結腸損傷評分......................................... 64 九、結腸骨髓過氧化酵素活性測定........................... 64 十、結腸中Glutathione測定................................ 66 十一、結腸中細胞激素TNF-α測定........................... 68 十二、結腸中細胞激素IL-10測定............................ 70 十三、結腸中iNOS表現量................................... 71 伍、結論................................................. 76 陸、參考文獻............................................. 78 附錄..................................................... 89 附表一、TNBS 誘導前大鼠體重變化...........................89 附表二、TNBS 誘導後大鼠體重變化.......................... 90 附表三、動物實驗申請案審查同意書......................... 91 | |
dc.language.iso | zh-TW | |
dc.title | Lactobacillus plantarum BCRC 11697之胞外多醣對於TNBS誘導老鼠結腸炎之影響 | zh_TW |
dc.title | Effects of exopolysaccharides from Lactobacillus plantarum BCRC 11697 on trinitrobenzene sulphonic acid (TNBS) - induced rat colitis | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蔡國珍(Guo-Jane Tsai),潘崇良(Chorng-Liang Pan),丘志威(Chih-wei Chiu),顏聰榮(Tsong-Rong Yan),周正俊(Cheng-chun Chou) | |
dc.subject.keyword | 胞外多醣,發炎性腸道疾病,三硝基苯磺酸,抗發炎, | zh_TW |
dc.subject.keyword | exopolysaccharides,inflammatory bowel disease (IBD),trinitrobenzene sulfonic acid (TNBS),anti-inflammatory, | en |
dc.relation.page | 91 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2012-07-24 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 食品科技研究所 | zh_TW |
顯示於系所單位: | 食品科技研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 3.02 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。